<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES
13D-1(B) AND (C) AND AMENDMENTS THERETO FILED PURSUANT TO 13D-2(B)
(Amendment No. 4)(1)
Interneuron Pharmaceuticals, Inc.
-------------------------------------------------
(Name of Issuer)
Common Stock, $.001 par value
-------------------------------------------------
(Title of Class of Securities)
460573 10 8
-------------------------------------------------
(CUSIP Number)
1 The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE> 2
- ------------------------------ -------------------------
CUSIP NO. 460573 10 8 13G PAGE 2 OF 5 PAGES
--------------------- ----- -----
- ------------------------------ -------------------------
- -------------------------------------------------------------------------------
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Lindsay Rosenwald, M.D.
###-##-####
- -------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) [ ]
(B) [ ]
- -------------------------------------------------------------------------------
(3) SEC USE ONLY
- -------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- -------------------------------------------------------------------------------
(5) SOLE VOTING POWER
NUMBER OF 2,638,485
SHARES --------------------------------------------------------
BENEFICIALLY (6) SHARED VOTING POWER
OWNED BY 0
EACH --------------------------------------------------------
REPORTING (7) SOLE DISPOSITIVE POWER
PERSON WITH 2,638,485
--------------------------------------------------------
(8) SHARED DISPOSITIVE POWER
0
- -------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,638,485
- -------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES* [ X ]
- -------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
6.4%
- -------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 3
Page 3 of 5
Item 1(a). Name of Issuer :
Interneuron Pharmaceuticals, Inc. (the "Issuer")
Item 1(b). Address of Issuer's Principal Executive Offices:
One Ledgemont Center
99 Hayden Avenue
Lexington, Massachusetts 02173
Item 2(a). Name of Person Filing:
Lindsay Rosenwald, M.D.
Item 2(b). Address of Principal Business Office or if none, Residence:
787 Seventh Avenue
New York, New York 10019
Item 2(c). Citizenship:
United States
Item 2(d). Title of Class of Securities:
Common Stock, $.001 par value ("Shares")
Item 2(e). CUSIP Number:
460573 10 8
Item 3. Not Applicable
<PAGE> 4
Page 4 of 5
Item 4. Ownership:
(a) As of December 31, 1997 Dr. Rosenwald beneficially
owned 2,638,485 Shares.
Includes (i) 7,671 Shares issuable upon exercise of
outstanding warrants, (ii) 300,000 Shares which have
been pledged in favor of a bank to secure certain
lease obligations of an associate of Dr. Rosenwald
and (iii) 118,333 Shares issuable upon exercise of
options which are exercisable within 60 days.
Excludes (i) 66,667 Shares issuable upon exercise of
options which, as of December 31, 1997, were not
exercisable within 60 days, (ii) 658,481 Shares owned
by Dr. Rosenwald's wife, as to which Shares Dr.
Rosenwald disclaims beneficial ownership and (iii)
37,800 Shares owned by two limited partnerships, the
limited partners of which include Dr. Rosenwald's
wife and children, as to which Shares Dr. Rosenwald
disclaims beneficial ownership.
(b) Percent of Class: 6.4%.
(c) (i) Number of shares as to which such person has
sole power to vote or direct the vote:
2,638,485.
(ii)-(iv) Reference is made to items 6-8 of the
cover page.
Item 5. Ownership of Five Percent or Less of a Class
Not Applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not Applicable
Item 7. Identification and Classification of Subsidiary Which Acquired
the Securities
Not Applicable
Item 8. Identification and Classification of Members of the Group
Not Applicable
<PAGE> 5
Page 5 of 5
Item 9. Notice of Dissolution of Group
Not Applicable
Item 10. Certification
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
FEBRUARY 11, 1998
- -----------------------------------------------
Date
/s/ Lindsay Rosenwald
- -----------------------------------------------
Signature
LINDSAY ROSENWALD, M.D.
- -----------------------------------------------
Name/Title
